Jonas Karl Olaf Brambeck
Direttore/Membro del Consiglio presso Gesynta Pharma AB
Posizioni attive di Jonas Karl Olaf Brambeck
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Industrifonden
 Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | Investitore di Private Equity | 01/01/1998 | - |
Avidicare AB
 Avidicare AB Medical DistributorsDistribution Services Avidicare AB operates as a medical device company. It specializes in the management of airborne bacteria and virus pollution at hospitals. The firm provides Opragon, a ventilation system for reduction of airborne bacterial contamination in various hospital environments primarily for infection sensitive surgery. The company offers Opragon for preparation rooms, operating theaters, and hybrid rooms; and air curtains and external air showers. Avidicare was founded in 2010 and is headquartered in Lund, Sweden. | Corporate Officer/Principal | - | - |
Airsonett AB
 Airsonett AB Medical DistributorsDistribution Services Airsonett AB is a holding company that is engaged in the research and development of a non-pharmaceutical treatment for asthma. Its product Airsonett is based on temperature controlled Laminar Airflow technology that creates a radically reduced allergen exposure in the breathing zone for treatment of asthma, allergic rhinitis, and atopic eczema. The company was founded by Jan Tommy Lennart Hedberg, Jan Kristensson, and Dan Kristensson in 2000 and is headquartered in Ängelholm, Sweden. | Corporate Officer/Principal | - | - |
Gesynta Pharma AB
 Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Jonas Karl Olaf Brambeck
Precedenti posizioni note di Jonas Karl Olaf Brambeck
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Resistentia Pharmaceuticals AB
 Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Direttore/Membro del Consiglio | 01/01/2000 | 24/06/2010 |
Quiatech AB
 Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Direttore/Membro del Consiglio | - | 30/08/2007 |
| BOULE DIAGNOSTICS AB | Direttore/Membro del Consiglio | 01/01/2002 | - |
OLIGOvation AB
 OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Direttore/Membro del Consiglio | - | - |
| ONCOPEPTIDES AB | Direttore/Membro del Consiglio | 01/01/2008 | - |
| Independent Dir/Board Member | 01/01/2008 | - | |
| ░░░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░ ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formazione di Jonas Karl Olaf Brambeck
| Royal Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
| Svezia | 18 |
| Danimarca | 2 |
| Stati Uniti | 2 |
Posizioni
| Director/Board Member | 12 |
| Corporate Officer/Principal | 5 |
| Private Equity Investor | 1 |
Settori
| Health Technology | 12 |
| Commercial Services | 3 |
| Finance | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| BOULE DIAGNOSTICS AB | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| SLOTTSVIKEN FASTIGHETSAKTIEBOLAG | Finance |
| Aziende private | 15 |
|---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
Quiatech AB
Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Health Technology |
OLIGOvation AB
OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Commercial Services |
Industrifonden
Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | Finance |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
RSPR Pharma AB
 RSPR Pharma AB Pharmaceuticals: MajorHealth Technology RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
| Bruker Instruments, Inc. | |
Nobel Biocare AB
 Nobel Biocare AB Medical SpecialtiesHealth Technology Nobel Biocare AB provides esthetic dental solutions. The firm offers crown, bridge and implant products, as well as training & education and clinically documented treatment concepts. Its solutions enable dental specialists, general practitioners and dental technicians to offer patients esthetic new teeth. The company is headquartered in Goteborg, Sweden. | Health Technology |
CMC Contrast AB
 CMC Contrast AB Pharmaceuticals: MajorHealth Technology CMC Contrast AB develops magnetic resonance contrast agents for patients suffering with tumors. Its product CMC 001 is a Manganese containing orally administered magnetic resonance imaging (MRI) contrast medium for enhancement of the liver, bile ducts and gastrointestinal tract. The company was founded by Henrik S. Thomsen in 2000 and is headquartered in Malmo, Sweden. | Health Technology |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
Avidicare AB
Avidicare AB Medical DistributorsDistribution Services Avidicare AB operates as a medical device company. It specializes in the management of airborne bacteria and virus pollution at hospitals. The firm provides Opragon, a ventilation system for reduction of airborne bacterial contamination in various hospital environments primarily for infection sensitive surgery. The company offers Opragon for preparation rooms, operating theaters, and hybrid rooms; and air curtains and external air showers. Avidicare was founded in 2010 and is headquartered in Lund, Sweden. | Distribution Services |
Airsonett AB
Airsonett AB Medical DistributorsDistribution Services Airsonett AB is a holding company that is engaged in the research and development of a non-pharmaceutical treatment for asthma. Its product Airsonett is based on temperature controlled Laminar Airflow technology that creates a radically reduced allergen exposure in the breathing zone for treatment of asthma, allergic rhinitis, and atopic eczema. The company was founded by Jan Tommy Lennart Hedberg, Jan Kristensson, and Dan Kristensson in 2000 and is headquartered in Ängelholm, Sweden. | Distribution Services |
Gesynta Pharma AB
Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Health Technology |
